ANRO reports its latest results today with options traders having shifted sharply toward protection in recent weeks — a stance that puts the options market well outside its recent comfort zone.
The shift in options positioning is the most dramatic signal heading into the print. The put/call ratio has climbed to 0.89, near its 52-week high of 0.89 and roughly one standard deviation above the 20-day average of 0.58. That's a meaningful pivot: as recently as mid-April, the PCR was running below 0.11, meaning calls were dominating by a wide margin. In six weeks, options traders have essentially flipped from overwhelmingly bullish positioning to defensive hedging — a shift that tracks closely with the stock's recent volatility.
The stock itself is up 7.7% over the past month to $24.53, but gave back 2.6% in the last week, and past prints offer context for why traders are cautious. Three of the four most recent earnings events produced negative next-day reactions, including drops of 14.7% and 15.3% in November 2025. The one exception — a March 2026 event — saw just a 0.4% first-day gain before falling 10.1% over the following five days.
Short interest adds a different layer to the story. At 6.9% of the free float, it is a legitimate short position — up roughly 9% on the month — though the borrowing market is unusually relaxed for a stock with that level of bearish activity. Cost to borrow has eased sharply, dropping more than 44% over the week to just 0.77%. Availability is wide, meaning there is no squeeze pressure or borrow constraint pointing toward forced covering into the print. The shorts appear comfortable.
Analyst opinion is firmly constructive but divided on upside magnitude. All but one covering firm carries a Buy or Outperform rating, and HC Wainwright reiterated its $50 target on Monday — nearly double current levels. Baird trimmed its target from $41 to $38 in early April while holding Outperform, and Jones Trading cut from $49 to $44. The lone cautious voice, Wedbush, holds a Neutral with a $21 target — just below where the stock trades today. The bull case hinges on ALTO-207 in Phase 2, the company's AI-driven biomarker platform, and a strong cash position (net cash of roughly $342 million) that limits near-term dilution risk. Bears point to the binary nature of clinical-stage assets, the prior ALTO-101 failure, and a timeline where the next key data readout from ALTO-207 is not expected until the second half of 2027.
With the stock trading at a $24.53 handle and the analyst consensus sitting at a mean target of $35.24, the report is less about near-term revenue — there is none — and more about whether management can provide a credible update on trial progress, cash runway, and the biomarker pipeline that justifies holding through a long development timeline.
See the live data behind this article on ORTEX.
Open ANRO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
